FDT is efficient for monitoring functional damage in OAG patients

Article

Frequency doubling technology (FDT) is successful in monitoring functional damage in the standard automated perimetry (SAP)-normal hemifield in eyes with open-angle glaucoma (OAG).

Frequency doubling technology (FDT) is successful in monitoring functional damage in the standard automated perimetry (SAP)-normal hemifield in eyes with open-angle glaucoma (OAG), states a study in the Journal of Glaucoma.

Dr Suguru Nakagawa et al. Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Gifu, Japan, performed the investigation on 39 OAG patients with low to normal intraocular pressure (IOP).

The Humphrey Field Analyzer was used to measure FDT perimetry with the N-30 full threshold protocol and SAP. This was used along with the 30-2 Swedish Interactive Threshold Algorithm-standard protocol for at least 3 years in all patients.

A linear mixed model was employed to measure time courses of the mean of the FDT threshold values and mean total deviations (TDs) in SAP-normal and abnormal fields.

The findings demonstrated a significantly negative change in the mean FDT threshold values in the SAP-normal hemifield. However, the mean changes in TD values by SAP were not statistically significant.

SAP-abnormal hemifield experienced a significantly more negative change in the mean TD values, but FDT threshold values presented with no significant differences between the two hemifields.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.